Drug Trial Radar · NCT03428217
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
444
Actual
Start
Apr 24, 2018
Primary completion
Aug 31, 2020
Study completion Jul 16, 2021
Sponsor
- Lead sponsor
- Calithera Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).
Conditions
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
Interventions
CB-839Drug
Oral glutaminase inhibitor
CabozantinibDrug
Oral receptor tyrosine kinase inhibitor
PlaceboDrug
Placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)Time frame: Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.14 months.
Locations
133 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Cancer Center
Phoenix, Arizona
The University of Arizona Cancer Center
Tucson, Arizona
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Salinas Valley Memorial Healthcare System
Salinas, California
St. Joseph Heritage Healthcare
Santa Rosa, California
Penrose Cancer Center, Research Department
Colorado Springs, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Florida Cancer Specialists
Fort Myers, Florida
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Florida Cancer Specialists
St. Petersburg, Florida
H.Lee Moffitt Cancer & Research Institute (Moffitt Cancer Center)
Tampa, Florida
Emory Winship Cancer Institute
Atlanta, Georgia
Georgia Cancer Center at Augusta University
Augusta, Georgia
Northwest Georgia Oncology Centers, PC
Marietta, Georgia
St. Luke's Mountain States Tumor Institute
Boise, Idaho
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
NorthShore University HealthSystem
Evanston, Illinois
AMITA Health Cancer Institute & Outpatient Center
Hinsdale, Illinois
Orchard Healthcare Research, Inc.
Skokie, Illinois
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois
Goshen Center for Cancer Care
Goshen, Indiana
East Jefferson General Hospital
Metairie, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana
University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
HealthPartners Institute, Regions Cancer Care Center
Saint Paul, Minnesota
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi
University of Mississippi Medical Center
Jackson, Mississippi
Mercy Hospital
Joplin, Missouri
HCA Midwest Health
Kansas City, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
San Juan Oncology Associates, PC
Farmington, New Mexico
Roswell Park Cancer Center
Buffalo, New York
North Shore Hematology Oncology Associates PC dba NY Cancer and Blood Specialists
East Setauket, New York
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.